Another meta-regression analysis of trials in patients with NSCLC provided no evidence of trial-level correlations (meta-regression R2, 0.08; 95% CI, 0–0.31) between treatment effects for PFS and OS for targeted therapies, such as EGFR inhibitors (16). Here, EGFR is linked to non-small cell lung carcinoma.